FBR Capital Starts Alexion Pharmaceuticals (ALXN) at Underperform; Sees 37% Downside
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
FBR Capital initiates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Underperform rating and a price target of $82.00, suggesting 37% downside.
Analyst Christopher James commented, "We are initiating coverage of Alexion Pharmaceuticals, Inc. (ALXN) with an Underperform rating and a 12-month price target of $82 per share. Alexion, a recognized pioneering biotechnology company, focuses on discovering drugs for patients with ultra-rare disorders. The franchise consists of Soliris (eculizumab), which is the first therapeutic approved for the treatment of both the blood disease paroxysmal nocturnal hemoglobinuria (PNH) and a form of anemia, atypical hemolytic uremic syndrome (aHUS); Strensiq for the treatment of the bone disease hypophosphatasia (HPP); and Kanuma for the treatment of the enzyme deficiency lysosomal acid lipase deficiency (LAL-D). Despite its strong penetration into the ultra-rare orphan drug market and its relatively healthy pipeline, we believe ALXN is currently overvalued at a market capitalization of approximately $29B. While we are bullish on the overall rare disease space, we think ALXN shares are overpriced for the following reasons: (1) Alexion faces a competitive near-term landscape, particularly with Alnylam's ALN-CC5, albeit indirectly; (2) with the recent failed study with eculizumab in refractory generalized myasthenia gravis (gMG), we do not see significant near-term expansion into additional indications; and (3) we see possible additional pressures from pricing and biosimilars, including an Amgen biosimilar product in development."
Shares of Alexion Pharmaceuticals closed at $126.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades OneMain (OMF) to Neutral
- Deutsche Bank Starts Bruker (BRKR) at Hold
- Deutsche Bank Starts Agilent (A) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!